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Objective: The authors conducted a re-
view of the history and empirical basis of
genomewide association studies (GWAS),
the rationale for GWAS of psychiatric dis-
orders, results to date, limitations, and
plans for GWAS meta-analyses.
Method: A literature review was carried
out, power and other issues discussed,
and planned studies assessed.
Results: Most of the genomic DNA se-
quence differences between any two peo-
ple are common (frequency >5%) single
nucleotide polymorphisms (SNPs). Be-
cause of localized patterns of correlation
(linkage disequilibrium), 500,000 to
1,000,000 of these SNPs can test the hy-
pothesis that one or more common vari-
ants explain part of the genetic risk for a
disease. GWAS technologies can also de-
tect some of the copy number variants
(deletions and duplications) in the ge-
nome. Systematic study of rare variants
will require large-scale resequencing anal-
yses. GWAS methods have detected a re-
markable number of robust genetic asso-
ciations for dozens of common diseases
and traits, leading to new pathophysio-
logical hypotheses, although only small
proportions of genetic variance have
been explained thus far and therapeutic
applications will require substantial fur-
ther effort. Study design issues, power,
and limitations are discussed. For psychi-
atric disorders, there are initial significant
findings for common SNPs and for rare
copy number variants, and many other
studies are in progress.
Conclusions: GWAS of large samples
have detected associations of common
SNPs and of rare copy number variants
with psychiatric disorders. More findings
are likely, since larger GWAS samples de-
tect larger numbers of common suscepti-
bility variants, with smaller effects. The
Psychiatric GWAS Consortium is conduct-
ing GWAS meta-analyses for schizophre-
nia, bipolar disorder, major depressive
disorder, autism, and attention deficit hy-
peractivity disorder. Based on results for
other diseases, larger samples will be re-
quired. The contribution of GWAS will de-
pend on the true genetic architecture of
each disorder.
(Am J Psychiatry 2009; 166:540–556)
Since 2005 (1), genomewide association studies
(GWAS [je¯ ´ wo¯s])  have produced strongly significant evi-
dence that specific common DNA sequence differences
among people influence their genetic susceptibility to
more than 40 different common diseases (2). Many of
these findings implicate previously unsuspected candi-
date genes and new pathophysiological hypotheses. The
method is feasible because millions of human DNA se-
quence variations have been catalogued and new technol-
ogies have been developed that can assay more than one
million variants rapidly and accurately. The first GWAS re-
ports have appeared for psychiatric disorders, and nearly
50 GWAS are completed or will be reported soon for atten-
tion deficit hyperactivity disorder (ADHD), autism, bipo-
lar disorder, major depressive disorder, and schizophre-
nia. Additional studies are in progress. We formed an
international consortium of psychiatric GWAS investiga-
tors to carry out rapid meta-analyses of these five disor-
ders to maximize power. In the present overview, we de-
scribe GWAS methods, their rationale, and current results
for nonpsychiatric and psychiatric disorders as well as
limitations and uncertainties.
Candidate Genes, Linkage, and Linkage 
Disequilibrium
Genetic Epidemiology
Before any molecular genetic study is undertaken, the
methods of genetic epidemiology are used to identify a
phenotype (observable disease or trait) that is at least par-
tially heritable. An introduction to these methods is avail-
able online (http://www.dorak.info/epi/genetepi.html).
Briefly, twin, family, and population-based studies are
used to estimate heritability, define the most heritable
phenotype, and explore interactions between genetic and
environmental factors. The current diagnostic definitions
of major psychiatric disorders are based in part on twin
and family data. Epidemiological data are also critical for
defining appropriate comparison groups for molecular
studies. The data for psychiatric disorders suggest that
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most of the heritable risk is due to interactions of combi-
nations of genetic risk variants, each with a relatively small
effect on risk.
Candidate Genes
When the pathophysiology of a disease is known (e.g.,
an enzyme deficiency), it may be straightforward to define
candidate genes and to determine which DNA sequence
variants predict who becomes ill. For psychiatric disor-
ders, pathophysiologies are unknown. Most candidate
gene hypotheses are based on the effects of psychiatric
medications on monoamine neurotransmission, focusing
particularly on several functional polymorphisms in
dopaminergic or serotonergic pathways (i.e., sequence
variants that alter relevant receptor proteins or enzymes)
(3, 4). None has been shown to be associated with a psy-
chiatric disorder with a level of significance that would
lead to general acceptance of a finding.
Positional Methods
The alternative strategy is to localize disease-related se-
quence variation based entirely on its location or position
in the genome. Before GWAS, available methods included
the genomewide linkage study and linkage disequili-
brium mapping (of which GWAS is a large-scale example).
(See Table 1 for definitions and Table 2 for a timeline of
critical developments.)
Genomewide linkage studies became feasible in the
1980s, with genomewide "maps" (7) of hundreds of DNA
sequence variations (markers). Linkage analysis (reviewed
in [15]), of families with multiple ill members, exploits
within-family correlations between illness and the alterna-
tive sequences (alleles) of the markers that are closest to
the disease-related gene(s). Linkage studies led to the dis-
covery of mutations (mostly rare dominant or recessive)
for more than 1,600 diseases (see the Online Mendelian In-
heritance in Man [http://www.ncbi.nlm.nih.gov/Omim/
mimstats.html]). They have been less successful for com-
plex (multifactorial/multigenic) disorders. In psychiatric
linkage studies (catalogued online [https://slep.unc.edu]),
small samples of pedigrees were initially examined in the
hope of discovering simpler genetic mechanisms that
would provide clues to pathophysiology. Then, larger stud-
ies (involving hundreds of families) searched for genes
with smaller effects. There are diverse opinions regarding
the past success and future prospects of these studies. Sta-
tistically significant linkages have been reported but have
been difficult to replicate, presumably because linkage is
much less powerful when risk variants have small effects
and there is heterogeneity in the underlying genetic factors
in different families. Meta-analyses have supported linkage
for some disorders (16–18).
Linkage disequilibrium mapping relies instead on the
population-wide correlation between two sequence vari-
ants. Most variants are single nucleotide polymorphisms
(SNPs) (almost always just two alternative nucleic acids at
a genomic position). SNP variants that are reasonably
common are mutations that occurred thousands of gener-
ations ago and then spread due to chance or natural selec-
tion. When a second SNP mutation occurred very close to
an earlier one (separated by up to tens of thousands of base
pairs), then both variant alleles are almost always transmit-
ted to the same offspring in subsequent generations. Link-
TABLE 1. Definition of Terms
Term Definition
Heritability Proportion of the variance of a phenotype (disease, trait) that is due to genes, estimated from risks to twins 
and other relatives.
Mendelian disease Caused by a (usually rare) change (“mutation”) in DNA sequence on one (dominant) or both (recessive) of an 
individual’s pair of chromosomes.
Complex disease Caused by an interaction of multiple genetic and/or environmental factors.
SNPa Specific position (among 3.2 billion in the genome) where chromosomes carry different nucleic acids. 
Approximately 11 to 15 million SNPs with frequency ≥1%. Approximately 4 million are catalogued by the 
HapMap Project.
Common SNPs ≥5% frequency. Approximately 10 million in the genome; approximately 2.8 million on the current HapMap. 
These SNPs are targeted by GWAS.
Rare variants (rare SNPs)a <1% frequency; many of them very rare. Rarer SNPs in protein-coding regions tend to be more harmful (fre-
quency constrained by selection).
Copy number variant Chromosomal segment where DNA has been deleted or duplicated. Other structural variants include inver-
sions and translocations.
Common-disease common-
variant hypothesis
Some of the genetic risk to common diseases is due to common SNPs.
Multiple rare variant hypothesis Some of the genetic risk to common disease is due to many different rare SNPs, especially in protein coding 
or gene regulatory regions.
Linkage disequilibrium 
between SNPs
Correlation between two SNPs that are close together (an allele of one SNP is usually inherited with a specific 
allele from the other). Linkage disequilibrium makes GWAS possible: a subset of common SNPs gives infor-
mation about most of them.
Genomewide association study A systematic search for common SNPs that influence a disease or trait, using a genomewide SNP array for 
typing a cohort of individuals. Current arrays also provide information about copy number variants.
Genomewide SNP chip (array) A system for assaying 300,000 to 1,000,000 SNPs for an individual subject, using an array of bead-based or 
hybridization assays on a glass slide.
a The term “SNP” is sometimes reserved for single-position variants with a frequency ≥1% (i.e., found on at least 1% of chromosomes in a pop-
ulation). For variants with a frequency <1%, the terms “rare variants” and “rare SNPs” are both in use, although “variants” could also refer to
other types of sequence changes.
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age disequilibrium is this nonrandom association of two
alleles. Approximately 20 years ago, it was proposed that
linkage disequilibrium could be exploited to “map” or
identify disease genes, such as in linkage candidate regions
(or in recently isolated populations in which linkage dise-
quilibrium spans long distances) (19). If one SNP increases
the risk of a common disease, then there will be a statistical
association in the population between disease and that
SNP (direct association) and several nearby SNPs (indirect
association due to linkage disequilibrium).
Linkage disequilibrium mapping studies have identified
plausible positional candidate genes in regions of linkage
or of cytogenetic abnormalities associated with psychiat-
ric disorders, and these genes have suggested new mecha-
nistic hypotheses (20). For example, as of April 2008, there
were 1,291 published studies of 690 schizophrenia candi-
date genes (see http://www.schizophreniaforum.org/res/
sczgene/default.asp). A recent meta-analysis of these
studies (3) identified four “strong” psychiatric candidate
gene associations based on epidemiological criteria for
meta-analysis but not at what is currently understood to
be a genomewide level of statistical significance.
Common SNPs, HapMap, and GWAS
Risch and Merikangas (21) noted that small genetic ef-
fects could be detected with greater power by association
analyses and proposed that genomewide linkage disequi-
librium mapping (i.e., GWAS) could be applied if technol-
ogies were developed to study SNP frequencies in all
genes, contrasting ill case subjects versus comparison
subjects or case subjects and their parents (associated al-
leles are transmitted to ill offspring more often than ex-
pected by chance). Lander (9) proposed the common-dis-
ease common-variant hypothesis. Comparing any two
people, most sequence differences are ancient, “common”
SNPs (by convention, varying on at least 5% of chromo-
somes in a population), which Lander argued must confer
at least some (not all) of the genetic risk for common dis-
eases. He proposed cataloguing them and studying their
association with disease in large samples. SNPs become
common because they are neutral or favorable with re-
spect to survival (e.g., evolutionary pressures can rapidly
increase frequencies of adaptive SNPs in gene regulating
regions). However, some have mildly harmful effects, per-
haps depending on environmental conditions (e.g., pre-
serving fat during an ice age but leading to obesity in the
fast food era). The common-disease common-variant
GWAS strategy assumed that many different common
SNPs have small effects on each disease and that some
could be found by testing enough SNPs in enough people.
How many SNPs should be tested? Studies of small re-
gions revealed linkage disequilibrium blocks in which
TABLE 2. Timeline of Positional Genetic Methods From Linkage To Genomewide Association Studies
Year Development Comment
1980 Proposal to create a genomewide 
map of DNA markers for human 
linkage analysis (5).
Following the discovery of restriction fragment length polymorphism markers, it was pro-
posed that once restriction fragment length polymorphisms throughout the genome 
were available, it would be possible to search any genomic region, or the entire human 
genome, for evidence of genetic linkage.
1983 Linkage mapping and identifica-
tion of the Huntington’s disease 
gene (6).
The first of the many Mendelian disorders for which genetic linkage was detected followed 
by identification of specific disease mutations in the linkage region.
1987 First human linkage map (7). The first genomewide map of approximately 400 restriction fragment length polymor-
phisms ushered in the era of genomewide linkage studies. Restriction fragment length 
polymorphisms were supplanted by short tandem repeat markers and then SNPs.
1993 First genomewide linkage study of 
a psychiatric disorder (8).
Psychiatric genomewide linkage studies (catalogued online [https://slep.unc.edu]) pro-
duced some convergent linkage evidence, but no definitive evidence for susceptibility 
genes.
1996 Common-disease common-vari-
ant hypothesis (9).
The HapMap Project grew out of the need to develop a dense set of genetic markers to test 
this hypothesis.
2001 Draft of the complete human 
genome sequence (10).
The genome sequence set the stage for all future progress. It stimulated critical advances 
in genomic sequencing technology and set a new standard of immediate public release 
of government-supported genomic research data.
2002–2007 International HapMap Project (11, 
12) (www.hapmap.org).
The project discovered and genotyped (in 270 individuals from three populations) 1.3 mil-
lion SNPs in Phase I plus 2.1 million in Phase II— approximately 25% to 35% of common 
SNPs in these populations), providing good genomewide coverage. It spurred advances in 
SNP assays, making genomewide association studies possible. “HapMap III” provided gen-
otypes in an expanded data set for the Illumina 1M and Affymetrix 6.0 (900K) SNP sets.
2002 First published genomewide asso-
ciation study (13).
This study of myocardial infarction used few SNPs (65,761) and cases (94) by current stan-
dards.
2005–2007 Availability of high-throughput 
array-based SNP assays.
Affymetrix and Illumina arrays became available, initially with approximately 100,000 
SNPs, and currently with up to approximately 1 million SNPs per array plus additional 
probes for analysis of copy number. These have made it possible to carry out genome-
wide association studies for many diseases and samples.
2005 First year with multiple genome-
wide association study publica-
tions.
The first small studies using denser SNP sets produced strong associations for macular de-
generation (1) and Crohn’s disease (14), demonstrating the feasibility and power of 
genomewide association studies.
2007 Initiation of the 1,000 Genomes 
Project (www.1000genomes.org).
This project aims to extend the HapMap to all SNPs with 1% frequency in diverse popula-
tions, functional SNPs of lower frequencies, and sequence-level data on structural 
variants, utilizing multiple high-throughput sequencing technologies.
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common SNPs are highly correlated (usually <10,000–
30,000 base pairs in African populations or 30,000–50,000
base pairs in the newer European and Asian populations)
(22). This motivated the HapMap Project (www.hap-
map.org [12]), which has validated approximately 4 mil-
lion SNPs, including 2.8 million of the estimated 10 mil-
lion common SNPs in major world populations, while
creating competition among biotechnology companies to
develop high-throughput genotyping technologies. Se-
quencing and genotyping studies showed that sets of
500,000 (European populations) to 1,000,000 (African
populations) SNPs could “tag” (serve as proxies for) ap-
proximately 80% of common SNPs (23). Over the last 3
years, the Affymetrix and Illumina companies have devel-
oped “chips” (arrays of assays on glass slides) that assay
large SNP sets with high accuracy (0%–2% missing data;
<0.5% errors), at low cost (approximately $500 [U.S.] per
subject; an approximate 2,000-fold reduction in cost per
genotype in 10 years), and rapidly (>1,000 DNA specimens
per week in some labs). Thus, the GWAS era has arrived.
Rare SNPs
Common SNPs are unlikely to explain all of the genetic
risk for common disorders. An evolutionary model of
complex diseases (24) predicts roles for common SNPs
and for multiple rare variants (such as SNPs) in some
genes (multiple rare variant hypothesis). A rare variant is
usually defined by a frequency <1%, although many are so
rare that they are found in only one individual in a sample
(25). Most variants carried by any one person are com-
mon, but if one sequences a chromosomal region in many
people, one finds more rare SNP sites. The most deleteri-
ous variants die out or remain rare due to natural selection
(i.e., they reduce survival). They are found in functional re-
gions (i.e., among the SNPs in exons [protein coding re-
gions]) that alter amino acid sequence (nonsynonymous
SNPs) or in promoters (sequences that regulate gene ex-
pression) (26, 27). However, there are other poorly under-
stood functional regions. Many noncoding regions are
highly conserved across species, suggesting that they have
a function. Gene expression can be altered by common,
synonymous exonic SNPs (no coding change) and by SNPs
in introns (noncoding gene segments) (28). Indeed, most
genomic DNA is apparently transcribed into RNA and thus
could have unknown regulatory functions (29). Most rare
SNP associations will be missed by current GWAS meth-
ods, but it is expected that the 1,000 Genomes Project
(www.1000genomes.org) will discover most SNPs with
1%–5% frequencies, which would permit an extension of
systematic GWAS methods to these less common SNPs.
Linkage could detect a locus with rare pathogenic variants
in many families.
Rare SNP associations are more likely to be detected by
resequencing of relevant regions in hundreds or thou-
sands of individuals. (By convention, resequencing, which
is sometimes now referred to as “medical sequencing,” de-
termines an individual’s DNA sequence versus sequencing
of an organism’s genome.) Botstein and Risch (30) encour-
aged the systematic study of nonsynonymous SNPs in
common diseases. Multiple rare pathogenic variants have
been discovered by resequencing genes influencing lipid
metabolism (31) and hypertension (32) and also genes for
which GWAS have already detected common-SNP associ-
ations (33–35). It is anticipated that advances in rese-
quencing technologies will make it feasible to search sys-
tematically for rare variant effects in parts of the genome
(e.g., linkage regions, all exons, all promoters) and eventu-
ally genomewide.
Copy Number Variants
GWAS technologies can also detect more of the copy
number variants in the genome than was possible with
older cytogenetic methods, by analysis of the relative in-
tensities of the fluorescent labels used in the assays. Copy
number variants are deletions and duplications of DNA
segments of diverse sizes and population frequencies. For
example, large deletions on chromosome 22q11 cause
velocardiofacial/DiGeorge syndrome, and 20% of patients
with this syndrome also develop schizophrenia (36). Copy
number variants tend to arise in regions with repetitive
DNA sequences. Some copy number variants are common
and transmitted from generation to generation, while oth-
ers recurrently arise de novo. Similar to rare SNPs, rare
copy number variants are more likely to be harmful.
(Other structural variants, such as inversions and translo-
cations, remain difficult to detect.) Large genomewide
copy number variant scans show that copy number vari-
ants are more common than previously recognized (37).
Structural variation has not been as comprehensively
studied as SNPs because copy number variant detection is
less accurate, biological confirmation remains costly, and
smaller copy number variants (<100,000 base pairs) are
less reliably detected. However, technologies are rapidly
improving. Significant copy number variant findings are
now being reported for psychiatric disorders.
GWAS Study Design
Study design issues are summarized in Table 3. A GWAS
sample, selected based on a well-defined heritable pheno-
type, might include case subjects (ill) and comparison
subjects, subjects with a range of values for a continuous
phenotypic variable, or probands and both of their par-
ents (trios) or other constellations of relatives. Samples are
often limited to a single ancestry (European, Asian, etc.)
because some SNPs have markedly different frequencies
across populations (and some are not observed in every
population) so that some associations can best be de-
tected in homogeneous samples. Each subject is geno-
typed using a GWAS SNP array. Extensive “quality control”
(data cleaning) is required to detect problems that can re-
sult in false negative or false positive findings, such as
SNPs and DNA specimens that give poor quality results or
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unexpected relatedness among subjects. Case-control dif-
ferences in ancestry (“population substructure”) can also
confound association test results, but this can be cor-
rected statistically based on correlations among SNP gen-
otypes that reflect ancestry (38). Most studies then test
each SNP for association of genotypes to the phenotype
and impute the genotypes of other HapMap SNPs based
on the correlations among SNPs in HapMap data (39–41).
Selection of comparison groups is critical beyond the
problem of ancestral matching. It is ideal to recruit case
subjects and comparison subjects systematically from the
same population. This is not always feasible for very large
samples of a clinically severe disorder, but comparison
subjects must be sufficiently comparable with case sub-
jects to avoid systematic biases. Depending on the pheno-
type, it might be important to match for variables such as
age (e.g., for an Alzheimer’s disease study) or sex. Informa-
tion about known gene-environment interactions should
be considered (e.g., in studies of substance dependence,
comparison subjects are usually selected who have used
the substance but did not become dependent). When the
phenotype is relatively uncommon (e.g., 5% prevalence),
little power is lost by studying comparison subjects with-
out clinical screening, but for more common disorders,
power is increased if ill individuals are excluded from the
comparison group (40). It is reassuring that in the United
Kingdom Wellcome Trust Case Control Consortium GWAS
of seven common diseases, robust results were obtained
when association was tested using comparison groups
recruited from blood donors or from a population-based
birth cohort.
Statistical Power of GWAS
A key factor in the recent success of GWAS has been the
assembling of large samples with adequate statistical
power to detect small effects of common SNPs on disease
risks. Figure 1 illustrates the reasons for this. Large geno-
typic relative risks (e.g., 5- to 10-fold increase in risk to car-
riers) would have produced large linkage signals. Early
GWAS analyses of several hundred case subjects were
powered to search for risk alleles with genotypic relative
risks above 2. Only a few such effects were detected (1).
The more typical GWAS has included 1,000 to 2,000 case
subjects plus a similar number of comparison subjects,
with power to detect risk alleles that are reasonably com-
mon and have genotypic relative risks of 1.5 to 2. The small
number of robust findings suggested the need to detect
smaller genotypic relative risks (2).
This led to much larger GWAS analyses in collaborative
samples, which have proven to be remarkably successful
for many diseases. Most of the new, highly significant find-
ings have been for alleles with genotypic relative risks of
1.1 to 1.4 (mostly between 1.12 and 1.20). In this range
(Figure 1), good or excellent power requires samples of
8,000 to 20,000 case subjects (plus comparison subjects),
depending on genotypic relative risk and allele frequency
(i.e., larger than any sample collected by a single research
group to date).
GWAS Findings for Nonpsychiatric Disorders and 
Lessons for Psychiatry
Over the past 3 years, many highly significant GWAS
findings have been reported for nonpsychiatric disorders.
Table 4 summarizes a systematic listing of GWAS findings
TABLE 3. Genomewide Association Study Design Issues and Requirements
Issue Requirement Comment
Phenotype Well-defined, adequately heritable disorder (e.g., schizophrenia) or 
trait (e.g., high-density cholesterol level or neuroticism score).
Power depends on the frequency and effect size 
for individual variants, not overall heritability.
Sample type Ill case subjects and comparison subjects or subjects with a range of 
trait scores (e.g., highest and lowest) or case subjects and their par-
ents or other relatives.
Case/comparison subjects have more power per 
subject but are prone to mismatch biases (e.g., 
ancestry).
Comparison 
subjects
Match for ancestry, other relevant attributes (e.g., age for an Alz-
heimer’s disease study) or environmental exposures (e.g., “ever 
smoked” for a study of nicotine dependence).
For more common disorders, comparison sub-
jects with the disorder may be excluded to 
avoid false negative results (40).
Sample size Depends on the actual frequency and genetic effect of risk variants in 
the sample.
Samples up to tens of thousands of subjects 
have proven useful, but some common risk 
variants cannot feasibly be detected.
SNPs 300,000 to 1,000,000 common SNPs, depending on ancestry of the 
sample.
Goal is direct or indirect assay of 80% of HapMap 
II common SNPs with a correlation (r2) of ≥0.8.
Multiple testing P value correction for multiple, partially correlated genotyped SNPs, 
plus imputed data for all HapMap SNPs to permit cross-study com-
parison and meta-analysis (40, 41).
Genomewide significance threshold of approxi-
mately 5×10–8 (42–44).
Population sub-
structure
World populations differ in frequencies of many SNPs. Case subject-
comparison subject ancestry differences can create false positive 
and negative results.
Match case/comparison subjects for ancestry; 
apply statistical correction for population 
differences (38).
Data management Billions of data points to manage. Requires powerful computers or computer 
clusters and software (76).
Quality control Extensive quality control analyses are required to exclude poorly per-
forming SNPs and DNA specimens, identify duplicate or closely-
related specimens, and more subtle assay and sample problems.
Without adequate quality control, spurious 
highly “significant” findings are common.
Detection of copy 
number variants
Computational methods to detect copy number change from intensi-
ties of fluorescent labels in assays; additional nonpolymorphic 
assays can be added to improve copy number variant detection.
Copy number variant detection is less specific, 
sensitive, or accurate than SNP genotype de-
tection. Biological confirmation is needed.
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provided by the National Institute for Human Genome Re-
search (http://www.genome.gov/GWAstudies/ [accessed
Nov. 2008, refs. 42–44]), restricted to findings with p values
<5×10–8. There are 200 distinct findings listed for 59 disor-
ders or traits. Some may be false positives due to chance
(every p value is an estimate of the probability of a false
positive result) or to technical problems such as genotyp-
ing or analytical errors. However, many of these findings
have already been replicated in independent samples, and
most robust p values replicate. These results far exceed all
previous robust associations for complex disorders. This
confirms that common SNPs explain part of the genetic
risk for these disorders, as predicted by the common-dis-
ease common-variant hypothesis. There are almost cer-
tainly also many common SNPs with smaller effects on
risk as well as rare and very rare SNPs and copy number
variants with diverse effect sizes.
Sample size. Most initial GWAS samples included 500 to
3,000 case subjects (plus comparison subjects) or as many
as 10,657 subjects for a continuous trait. One or more rep-
lication samples were usually then studied via collabora-
tion, totaling 2,000 to 8,000 subjects (case and comparison
subjects or case subjects and family members). For studies
with at least 1,000 case subjects, most findings involved
common alleles (20%–80%), with odds ratios (estimates of
genotypic relative risk) between 1.1 and 1.4 (i.e., the range
within which there was some power).
Findings for type 2 diabetes illustrate the importance of
sample size. In late 2007, there were 11 strong candidate
genes. Of these, six were discovered by GWAS, four were
identified based on mechanistic hypotheses, and one,
TCF7L2, was identified by linkage disequilibrium map-
ping of a linkage region, although TCF7L2 SNPs did not ex-
plain the linkage (47). The TCF7L2 gene has an overall
odds ratio of 1.37. It was detected by most (not all) studies.
Other type 2 diabetes loci have allelic odds ratios between
1.1 and 1.2, requiring from 10,000 to well over 20,000 total
subjects for 80% power. Each locus was missed by most
single studies. For example, in the Wellcome Trust Case
Control Consortium study (2,000 case subjects; 3,000
comparison subjects), these 11 SNPs were ranked from 2
to 26,017 in their strength of association (47). Zeggini et al.
(48) combined more than 60,000 subjects to study type 2
diabetes findings that did not quite reach genomewide
significance previously. Six SNPs (implicating eight differ-
ent genes) have since achieved p values <5×10–8, with odds
ratios from 1.09 to 1.15.
Novel etiological hypotheses. Most findings have im-
plicated novel genes or regions and suggested new mech-
anisms. For example, SNPs in FTO (“fat mass and obesity
associated” gene) are strongly associated with common
obesity (49, 50). This was surprising because FTO knock-
out mice are not obese. Mechanisms are under study, in-
cluding a role in adipocyte lipolysis (51). As noted by Todd
(52), implicating a gene in disease requires both compel-
FIGURE 1. Relationship Among Power, Genotypic Relative Risk (multiplicative inheritance), and Sample Sizea
a The graphs show expected power (91) for a disease with 1% population prevalence (p=5×10–8), depending on minor (less frequent) allele fre-
quency of the tested SNP, sample size (assuming the number of case subjects shown in the graph legend and the same number of comparison
subjects, power is similar for the same number of case subject-parent trios), and genotypic relative risk, which is the ratio of the risk of disease
to carriers of a particular genotype versus non-carriers (thus, if genotypic relative risk is 1.2, risk is increased by 20%). The calculations assume
indirect association between a tested SNP allele and a risk allele at a correlation (r2) of 0.8, so that the effective sample sizes are approximately
80% of those shown. A sample of 8,000 case subjects and 8,000 comparison subjects will miss most associated alleles that confer much less
than a 20% increase in risk (genotypic relative risk <1.2), whereas 20,000/20,000 would detect most associated alleles with genotypic relative
risk=1.12 and frequency >15%–20%. Factors that affect power include: 1) Genotypic relative risk. Power increases with genotypic relative
risk. 2) Allele frequency and linkage disequilibrium. Power increases with the minor allele frequency of the associated SNP and with stron-
ger linkage disequilibrium between the SNP and an untested risk allele. 3) Mode of transmission. Power is greater for dominant and multi-
plicative (log additive) genetic effects and less for recessive effects (particularly for rare alleles). 4) Selection of comparison subjects. For dis-
eases with higher prevalence (e.g., >5%), power increases if comparison subjects with the disorder/trait of interest are excluded. (40). 5)
Technical artifacts of all kinds can reduce power.
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ling statistical evidence for association and substantial ad-
ditional biological evidence.
Insights into phenotypes. FTO also exemplifies the im-
portance of phenotypic variables. Type 2 diabetes is com-
mon in obese individuals. FTO SNPs are associated with
type 2 diabetes, but this is due to the association between
type 2 diabetes and body mass index (50). The association
of FTO with type 2 diabetes is not found when type 2 dia-
betes case and comparison subjects are matched for body
mass index (53). Surprising relationships among pheno-
types have also been discovered. For example, SNPs on
chromosome 8q24.21 are associated with prostate, breast,
and colorectal cancers, which were not previously thought
to be genetically related (54). The region contains no
known genes, and thus it would have been ignored with-
out a GWAS strategy. It is now being intensively studied.
Thus, GWAS have been remarkably successful for many
common diseases. Large multicenter samples have usu-
ally been required, and larger samples have detected more
associations. Only a small part of the genetic risk for any
one disease has been explained, but these discoveries
have suggested new disease mechanisms and targets for
therapy and prevention, although direct therapeutic ap-
plications will require substantial additional effort to char-
acterize the biological mechanisms and develop new
treatments. Some of the unexplained variance is likely due
to other common SNPs (those that have smaller effects
than can be detected with current sample sizes or are not
tagged by the arrays or are missed because of technical or
sampling problems). The remaining variance may be due
to rare SNPs, copy number variants, other unsuspected
genomic mechanisms, gene-gene or gene-environment
interactions that have not been adequately modeled, and
epigenetic effects. The results suggest that the largest pos-
sible samples should be studied by GWAS for each of the
major psychiatric disorders to test the hypothesis that
common SNPs or detectable copy number variants are in-
volved in etiology. Positive findings could lead to impor-
tant etiological discoveries.
GWAS of Psychiatric Disorders
GWAS findings are now emerging for psychiatric disor-
ders (Table 5). The early findings include replicated copy
number variant associations for schizophrenia and autism,
a genomewide significant association for bipolar disorder
that emerged when several data sets were combined, and a
significant association in a combined schizophrenia-bi-
polar data set.
For schizophrenia, four genomewide studies of copy
number variants (55–58) have produced two types of rep-
licated findings. First, two large studies (55, 56) found two
rare deletions that are significantly associated with schizo-
phrenia on chromosomes 1q21.1 (0.2% of case subjects)
and 15q13.3 (0.3% of case subjects). The case: comparison
subjects ratio (approximately 10) suggests major effects on
risk, but it is unknown which deleted genes or sequences
are responsible or whether they account for all of the sub-
jects’ genetic risks. These deletions are also found (but
probably less frequently) in individuals with mental retar-
dation and/or autism and are typically de novo (not inher-
ited from parents) (55). The well-known chromosome
22q11 deletions were also significantly associated with
schizophrenia (0.2%–0.4% of case subjects across studies
versus 0% of comparison subjects). Second, the three
studies (56–58) that tested such a hypothesis showed that
schizophrenia case subjects have a small but significant
increase in their total genomewide count of rare long copy
number variants, suggesting that there are other patho-
TABLE 4. Significant Genomewide Association Study Findings for Nonpsychiatric Disordersa
Type of Disease or Trait Unique Findings With p≤5×10–8 Number of Disorders or Traits
Autoimmune 12 3
Bone density 10 1
Cancer 37 8
Cardiovascular 5 4
Diabetes type 1 10 1
Diabetes type 2 10 1
Gastrointestinal 25 5
Lipid levels 13 3
Neurological 9 6
Physical traits 28 7
Plasma values 22 10
Other 19 10
Total 200 59
a There is no definitive p value threshold that predicts true positive genomewide association study findings. Interpretation rests on consistency
of replication and/or meta-analysis of cumulative data. A p value threshold of 5×10–8 has been used throughout this review, based on three
estimates that assumed that all common SNPs have been tested (42–44), but other thresholds can be defended. Other approaches include
false discovery rate (45) or Bayes Factor (41, 46) criteria. Shown for each category is the number of distinct findings (defined as one or more
SNPs in a single chromosomal band for a specific disease or trait) with a p value ≤5×10–8, counting only once those findings reported more
than once. Of the 200 findings, 95 had p values <10–12, and 58 had p values <10–15. Some SNPs or regions have produced findings for differ-
ent disorders or traits (see article). In many cases, there are additional studies or meta-analyses (not included in this tabulation of genome-
wide association study reports) that contain additional findings or updated significance levels. “Physical traits” includes nondisease traits such
as hair and eye color and height. “Plasma values” includes studies of potentially disease-related values (other than lipids) such as C-reactive
protein, glucose, and IgE. “Other” includes studies related to eye, skin, or pulmonary diseases; obesity-related traits; aging; and other traits.
Data are summarized online (http://www.genome.gov/GWAstudies/ [accessed November 2008]).
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TABLE 5. Published Genomewide Association Studies of Psychiatric Disordersa
Item Disorder
Initial Sample (case subjects/
comparison subjects) Other Data Genomewide Significant Findings
Studies of association to SNP genotypes (individual genotyping)
Wellcome Trust 
Case Control 
Consortium (41)
Bipolar 
disorder
1,868/2,938 (United Kingdom)
Sklar et al. (59) Bipolar 
disorder
1,461/2,008 (United States, 
United Kingdom, Systematic 
Treatment Enhancement Pro-
gram for Bipolar Disorder 
(STEP-BD)-University College of 
London)
Replication sample (for best 
results): 409 U.S. trios; 365 
case subjects/351 comparison 
subjects (Scottish)
Ferreira et al. (60) Bipolar 
disorder
4,387/6,209 Wellcome Trust Case Control Con-
sortium (41) plus Sklar (59) (see 
numbers above) plus ED-DUB-
STEP2 (1,098 case subjects/
1,267 comparison subjects)
p=9.1×10–9ANK3 gene (odds ratio=1.45; 
frequency of the associated allele in 
comparison subjects=0.053)
Lencz et al. (61) Schizo-
phrenia
178/144 (United States)
Sullivan et al. (62) Schizo-
phrenia
738/733 (United States) Multiple ancestries
O’Donovan et al. 
(63)
Schizo-
phrenia
479/2,937 (United Kingdom) plus 
1,865 Wellcome Trust Case 
Control Consortium bipolar 
disorder case subjects
Replication sample (for best re-
sults): 6,829 case subjects/9,897 
comparison subjects (United 
Kingdom, Europe, United 
States, Australia, Japan, Israel
With bipolar disorder included: 
p=9.96×10–9; ZNF804A gene (odds 
ratio=1.12; frequency of the associated 
allele in comparison subjects=0.59)
Studies of association to copy number variants
Walsh et al. (57) Schizo-
phrenia
150/268 Replication sample (for best 
results): 83 childhood-onset 
schizophrenia patients plus 
parents
p=0.0008; increased novel copy number 
variants in case subjects (15%) versus 
comparison subjects (5%) (p=0.03 in 
child-onset schizophrenia)
Xu et al. (58) Schizo-
phrenia
152/159 Sporadic case subjects p=0.0008; increased noninherited copy 
number variants in sporadic case sub-
jects (9.9%) versus comparison subjects 
(1.26%)
Stone et al. (56) Schizo-
phrenia
3,381/3,191 p=3×10–5; increased copy number vari-
ants (<1% frequency; >100Kb) in case 
subjects (1.14% per subject) versus com-
parison subjects (0.99). Genomewide 
significant evidence for association of 
copy number variants on chromosome 
1q21.1, 22q11.2, 15q13.3.
Stefansson et al. 
(55)
Schizo-
phrenia
1,433/33,350 Replication sample (for best 
results): 3,285 case subjects/
7,951 comparison subjects
Genomewide significant evidence for asso-
ciation of copy number variants on 
1q21.1, 22q11.2, 15q11.2, 15q13.3
Sebat et al. (64) Autism 118 (sporadic)/196 Some comparison subjects from 
autism families; some Autism 
Genetics Resource Exchange 
families
Increased de novo copy number variants in 
case subjects (10%) versus comparison 
subjects (1%); (note: >1 comparison 
subject per family)
Kumar 2008 (65) Autism 180/372 Replication sample (for best 
results): 532 case subjects/465 
comparison subjects
p=0.044 (uncorrected); increased 16p.11.2 
deletions in case subjects (0.6%) versus 
comparison subjects (0%)
Marshall et al. 
(66)
Autism 427/500 Replication sample (for best 
results): 1,152 additional 
comparison subjects
Genomewide significant evidence for 
association of increased de novo copy 
number variants in case subjects (7%) 
versus comparison subjects (1%). 
Increased 16p.11.2 deletions in case 
subjects (approximately 1%) versus 
comparison subjects (0%); (p=0.002)
Weiss et al. (67) Autism 751 multiplex Autism Genetics 
Resource Exchange families 
(1,441 case subjects) plus 2,814 
comparison subjects
Replication samples (for best 
results): 512 case subjects/434 
comparison subjects; 299 case 
subjects/18,834 comparison 
subjects
Increased 16p.11.2 copy number variants 
in case subjects (1.1%) versus compari-
son subjects (0.05%); significant in all 
three samples
Christian et al. 
(68)
Autism 397/372 Case subjects from Autism Gene-
tics Resource Exchange families
11.6% of case subjects had a copy number 
variant unique to case subjects
a The copy number variant studies of Sebat et al., Weiss et al., and Christian et al. all used some families from the Autism Genetics Resource
Exchange repository and thus are not entirely independent. SNP studies all used SNP arrays with 500,000 SNPs (Affymetrix 500K or 5.0) or
900,000 SNPs (Affymetrix 6.0). Some studies used more than one type of array. Copy number variant studies used array-based comparative
genomic hybridization and/or genomewide association study SNP arrays (Affymetrix or Illumina), with additional confirmation of some or all
results using additional methods (e.g., quantitative polymerase chain reaction, karyotyping, and other methods). Studies using pooled geno-
typing are not included but are cited in the article text.
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genic copy number variants that are too rare to detect sin-
gly. Other GWAS studies of psychiatric disorders are sum-
marized in Table 5.
At the time of this writing, there have been three pub-
lished small schizophrenia GWAS analyses using individ-
ual genotyping (61–63), with samples that included 178 to
738 case subjects. Two additional studies (69, 70) used
pooled genotyping. To date, no genomewide significant
finding has emerged for schizophrenia alone. However,
when the 12 “best” SNPs from a GWAS of 479 case subjects
and 2,937 Wellcome Trust Case Control Consortium com-
parison subjects were genotyped in an additional 7,308
schizophrenia case subjects and 12,834 comparison sub-
jects, and the 1,868 Wellcome Trust Case Control Consor-
tium bipolar disorder case subjects were added to the anal-
ysis, a genomewide significant p value was seen for a SNP
in a gene of unknown function (zinc finger protein 804A
[ZNF804A]) (63). This will require replication for these dis-
orders, both separately and combined. It illustrates the po-
tential importance of cross-diagnosis analyses, although
such analyses will increase the problem of multiple testing
and thus require very large samples for confirmation.
For autism, three studies (65–67) have reported associa-
tion with a rare (1% of case subjects), large, high-pene-
trance deletion on chromosome 16p11.2. There is also
support for the hypothesis that there is an excess of rare,
mostly de novo, copy number variants in approximately
10% of case subjects, although the role of these rare copy
number variants in autism remains to be proven (64, 65,
68). Autism GWAS analyses of common SNPs have yet to
be reported.
For bipolar disorder, three individual studies (41, 59, 60),
of 1,000 to 2,000 case subjects each, failed to detect signifi-
cant association, but the three data sets combined pro-
duced a p value of 9.1×10–9 for ankyrin-G (ANK3), the prod-
uct of which links membrane proteins, such as voltage-
dependent sodium channels, to the axonal cytoskeleton.
The larger analysis did not replicate a significant associa-
tion (for DGKH [diacylglycerol kinase, eta]) that had been
reported in a smaller study using pooled genotyping (71).
Among the reports that will be available in the near fu-
ture are the four psychiatric GWAS reports, supported by
the Genetic Association Information Network (fnih.org),
on schizophrenia, bipolar disorder, major depression, and
ADHD. Details and preliminary results are available online
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap). We
are not permitted to summarize these analyses pending
the initial publications by the investigators. The Genetic
Association Information Network is an example of a new
emphasis on rapid public sharing of genetic data to accel-
erate the process of discovery.
The Psychiatric GWAS Consortium
The first set of psychiatric GWAS analyses have demon-
strated that this methodology can work for psychiatric dis-
orders. The pattern observed in the bipolar disorder stud-
ies is particularly encouraging because it is consistent
with what has happened for nonpsychiatric diseases:
combining several smaller samples produced a significant
result as well as several other findings with modestly sig-
nificant p values in each individual study, which could
prove to be significant as more data become available (60).
These results support our expectation that multiple de-
finitive association findings will be detected for many psy-
chiatric disorders, often requiring large samples. We
therefore organized the Psychiatric GWAS Consortium,
which includes almost all known GWAS studies to date for
schizophrenia, bipolar disorder, major depressive disor-
der, ADHD, and autism (Table 6), contributed by 121 in-
vestigators from 61 institutions at the time of this writing
(as listed in the Acknowledgments). The Psychiatric GWAS
Consortium has the following three specific objectives:
1. Within-disorder meta-analyses of all available GWAS
data. These diagnoses are based on definitions that
produced maximum heritability estimates in genetic
epidemiological studies. Thus, disorder-specific
analyses represent our strongest hypotheses.
2. Cross-disorder analyses, including analyses of combi-
nations of disorders and of phenotypes observed in
two or more disorders (such as depression or psycho-
sis) based on the recommendations of an expert
committee. Because data are insufficient to deter-
mine what common cross-disorder etiological fac-
tors might exist, alternative phenotypes should be
explored. GWAS analyses have produced surprising
cross-disorder associations, such as those found for
cancers (54) and inflammatory bowel diseases (86),
which could also exist for psychiatric disorders given
the many common symptoms.
3. Analyses of comorbidities such as alcohol, nicotine,
and illicit drug use disorders, which disorders can be
studied across multiple case groups.
Additional exploratory analyses will be carried out by an-
alysts from participating research groups, generating new
hypotheses that can be tested as more samples become
available. All GWAS data used by the Psychiatric GWAS
Consortium will become available to the scientific com-
munity through data repositories (unless prohibited by the
original consents or institutional review board decisions).
A central analytical team in consultation with partici-
pating analysts will conduct uniform quality control anal-
yses and imputation of nongenotyped HapMap SNPs (to
permit combining of data). The disorder-specific work-
groups will design their own primary meta-analyses, with
additional workgroups to define other phenotypic and
cross-disorder analyses. Analyses will account for ethnic
substructure within samples and appropriate pairing of
case and comparison groups.
Depending on the genetic architecture of each disorder,
one or more primary analyses could have sufficient power
to detect genomewide significant evidence for associa-
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tion. For example, the largest analyses, with approxi-
mately 10,000 case subjects and 10,000 comparison sub-
jects, would have 80% power to detect a SNP with a
genotypic relative risk of 1.152 and p value <5×10–8—
assuming direct association with an allele with a fre-
quency of 0.25 and log-additive inheritance—or 57%
power for indirect association with an r2 value of 0.8.
Power would be reduced for smaller samples, less com-
mon alleles, and recessive effects. If there are many risk al-
leles in the genome with a sufficient effect size, there
would be substantial power to detect at least one. Meta-
analyses will be completed in 2009. Updated results will be
made available on the Psychiatric GWAS Consortium web-
site (http://pgc.unc.edu).
Discussion
There is a compelling rationale for applying GWAS
methods to very large samples for major psychiatric disor-
ders. Given that the pathophysiologies of these disorders
are unknown, genomewide studies provide an unbiased
way to search the genome for causative factors. Many suc-
cessful GWAS analyses have combined data from diverse
clinical samples and SNP arrays to obtain replicable find-
ings that point to new hypotheses about disease mecha-
nisms and treatment targets. The first significant psychiat-
ric GWAS findings have been reported (Table 5), using
large collaborative samples. It is hoped that meta-analyses
can produce multiple robust findings for psychiatric dis-
orders.
GWAS SNP arrays “cover” ≥80% of common HapMap
SNPs, and regional resequencing data suggest that most
unknown common SNPs are also being tested indirectly.
Within these limitations, GWAS methods test the com-
mon-disease common-variant hypothesis. Copy number
variants are also detected but less systematically or accu-
rately. The Psychiatric GWAS Consortium meta-analyses
will have reasonable power to detect common SNP associ-
ations for each disorder within the limitations illustrated
in Figure 1. However, it is possible that very few significant
associations might be detected for some disorders or
none. How far should we go with GWAS?
Past experience suggests that for some disorders as
many as 20,000 to 30,000 case subjects and a similar num-
ber of comparison subjects (or case subjects plus their
parents) could be required to obtain highly robust find-
ings. More data sets will be genotyped in the near future,
and the National Institute of Mental Health plans to col-
lect additional large schizophrenia and bipolar disorder
samples (http://grants.nih.gov/grants/guide/rfa-files/
RFA-MH-08-131.html). This raises important questions
regarding resource allocation. For example, the next phase
of genetic studies will involve a combination of increas-
ingly large GWAS analyses (for common SNP and copy
number variant associations) and resequencing studies
(for rare variants). It is not known how these and other re-
search investments should be optimally balanced.
To the extent that resources are available, we encourage
a long-term view, avoiding the well-known pattern of ini-
tial exuberance followed by disillusionment. The logic of
GWAS has been clear for more than 10 years (23). Results
have been remarkably consistent with expectations in the
sense that common SNP associations have been discov-
ered for many common disorders, particularly those that
have been studied with larger sample sizes. It is true that
initial GWAS results have explained only a small part of the
etiological variance for each disease, and it seems certain
that studies of copy number variants and rare SNPs will
also be critical in elucidating disease mechanisms. How-
ever, it is likely that common SNPs explain a larger portion
of the variance than that which can be determined with
existing sample sizes, with many common SNPs, each
with small effects, contributing collectively to a major por-
tion of genetic risk (24). As the number of associations in-
creases, the biological pathways underlying risk for each
disease become clearer. GWAS methods should be applied
systematically to major psychiatric disorders in large sam-
ples. The following caveats are important to consider:
TABLE 6. Summary of Psychiatric GWAS Consortium Genomewide Association Study Samples and Characteristics of Studied
Disordersa
Disorder Samples Case Subjects
Comparison 
Subjects Trios or Families 
Prevalence 
Rate (%) Heritability (%)
ADHD 6 1,418 0 2,443 4–12 70–80
Autism 6 652 6,000 4,661 0.3–0.6 90–100
Bipolar disorder 10 7,075 10,559 0 0.3–1.5 73–93
Major depressive disorder 9 12,926 9,618 0 5–18 31–42b
Schizophrenia 11 9,588 13,500 650 0.2–1.1 73–90
Total 42 31,659 26,945 7,772
a Data shown are expected combined sample sizes for meta-analysis of genomewide association study data by the Psychiatric GWAS Consor-
tium by the end of 2009. Data are reported for subjects of European-ancestry only; a small number of African American samples are also
available for schizophrenia and bipolar disorder. The case subjects are all independent (although independence is tested using genotypes).
For each disorder, comparison subjects used in more than one study are counted once; also, comparison subjects used for more than one
disorder are counted once in the Total, which is therefore less than the sum of the rows for the disorders. The column for “Trios or Families”
includes a sample of multiply-affected families for schizophrenia and trio or sib-pair families (with parents) for ADHD and autism. References
for prevalence and heritability are as follows: ADHD (72–74), autism (75, 76), bipolar disorder (77, 78), major depressive disorder (79–82), and
schizophrenia (83, 84).
b For major depression, higher estimates have been obtained in clinical samples (85) or using repeated interviews (81).
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1. Some disorders might not be amenable to GWAS (e.g.,
if all risk alleles have very low genotypic relative risks
or if genetic risks are conferred by multiple rare SNPs
or by copy number variants too small to be detected
reliably). Discoveries for these disorders might only
be possible with larger-scale resequencing studies.
2. Current diagnostic categories might be inadequate.
Endophenotypic variables (neuroimaging, electro-
physiological, neuropsychological, biochemical, and
other markers) might better index the underlying
gene effects (87), although none has yet proven more
heritable than diagnostic categories. These measures
are not usually available in large data sets.
3. Genetic heterogeneity reduces power. A low fre-
quency risk allele is an example of heterogeneity (i.e.,
most case subjects do not share that risk factor).
Power (Figure 1) is best for frequencies above approx-
imately 20% and poor for frequencies greatly below
10% unless genotypic relative risk is high. Heteroge-
neity might be increased in large multicenter sam-
ples. For example, despite the generally high inter-
rater reliability for these disorders, research groups
can have diagnostic “biases,” some of which could
correlate with specific risk alleles. However, power in-
creases with sample size despite some degree of mis-
classification, and classification is imperfect for many
medical disorders for which there are GWAS findings.
4. More needs to be learned about the selection of com-
parison subjects for psychiatric GWAS studies. It re-
mains possible that some findings will be con-
founded by systematic biases in comparison groups,
such as under-representation of developmental dis-
abilities. The field will need much larger comparison
groups ascertained by diverse methods and from
multiple ethnic populations.
5. For some disorders there might be no detectable
main effects of SNPs, only higher order gene-gene or
gene-environment interactions. However, main ef-
fects are often detectable even if interactions are er-
roneously excluded. Explicit tests of interactions (88)
or data mining might prove informative.
6. GWAS assays do not interrogate all common variants.
For each array type, some assays perform poorly and
some common SNPs are not or cannot be tagged.
7. Improved methods will be needed to provide more
systematic information about copy number variants
and their relationship to disease. Associated copy
number variant regions will require resequencing
studies of large numbers of subjects without copy
number variants to determine whether these regions
also contain rare, highly penetrant associated variants.
8. There are probably unknown genetic mechanisms.
We have only recently recognized the importance of
copy number variants, micro RNAs, long-range pro-
moters, and epigenetic factors (genomic effects other
than sequence changes such as DNA methylation
patterns) (89). The discovery that most of the genome
is transcribed suggests that many types of functional
sequence are undiscovered (12).
Bearing these risks and caveats in mind, we conclude
that GWAS methods have discovered a remarkable set of
robust common SNP association findings for a broad
range of diseases (90), now including an initial set of SNP
and copy number variant associations for psychiatric dis-
orders. It is reasonable to predict that studies of suffi-
ciently large samples can produce definitive discoveries of
genetic risk factors for psychiatric disorders and that these
discoveries will contribute to the definitive identification
of pathophysiological mechanisms for the first time.
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